Click on the presentation titles below to read the abstracts and to find out more about the speakers
 

DAY 1 - THURSDAY MAY 28th 2020


 

8:00 am

Registration and coffee

8:45 am


Welcome Speech
Carole Guillonneau, U1064 CRTI, Nantes, France


 

SESSION I - ADVANCED CELL THERAPY
Chairmen: Hans-Dieter Volk & Nathalie Labarrière

9:00 am

Reprogramming Human Immune Cells with CRISPR
Alexander Marson, University of California, San Francisco, USA

9:30 am

Overcoming barriers to efficacy for engineered T cells in solid tumors
Stanley Riddell, Fred Hutchinson Cancer Research Center, Seattle, USA

10:00 am

CAR Tregs in transplantation and autoimmunity
Ignacio Anegon, Inserm UMR 1064 - Center for Research in Transplantation and Immunology, LabEx IGO, FOCIS Center of Excellence, Nantes University

10:30 am

Coffee break

11:00 am

 

Presentation title tbc
Silvia Gregory, San Raffaele Telethon Institute for Gene Therapy, Milan, Italy
 

 11:30 am
 
 Selected communications
  • Enhancing CAR T-cell therapies with precision genome engineering - Philippe Duchateau, Cellectis
  • Increased anti-tumor efficacy of PD-1 deficient melanoma-specific human Lymphocytes - Lucine Marotte, CRCINA, UMR1232 INSERM, University of Nantes
  • Immunosuppressant-resistant T cell products for improved functionality in immunosuppressed patients - Leila Amini, Berlin Institute of Health, Center for Regenerative Therapies, Berlin Center for Advanced Therapies, Charité Universitätsmedizin Berlin – CVK


 

12:00 am

Lunch break & poster viewing session


 

SESSION II - TISSUE MICROENVIRONMENT
Chairmen: Barbara Seliger & Jérôme Martin

2:00 pm

 Immunoregulation of inflammation
  Renato Monteiro, Center for Research on Inflammation - INSERM U 1149 & CNRS ERL8252 / Paris   Diderot Faculty of Medicine
 

2:30 pm

Myeloid cells and cancer immunotherapy
Antonio Sica, Dept of Pharmacological Sciences, University of Eastern Piedmont, Novara / Head lab. Molecular Immunology, Humanitas Clinical and Research Center , Milan, Italy
 

 3:00 pm TIGIT and its cellular and bacterial ligands: new checkpoints for cancer immune therapy
Ofer Mandelboim, Institute of Medical Research Israel-Canada (IMRIC), University of Jerusalem, Israel
 

3:30 pm

Coffee break

4:00 pm


Immune escape mechanisms of tumors and their impact for immunotherapies
Barbara Seliger, Institute for Medical Immunology at the Martin-Luther-University Halle-Wittenberg, Germany

 4:30 pm Selected communications
  • IL-26 is a soluble innate receptor interacting with extracellular DNA - Caroline Poli, CRCINA, UMR1232 INSERM, University of Nantes
  • Critical Role of the Regulatory Cytokine IL-34 in Treg Function - Antoine Freuchet, CRTI, UMR 1064 INSERM, University of Nantes
  • Human microbiota-induced TREGS: potential roles in homeostasis and diseases - Emmanuelle Godefroy, CRCINA, UMR1232 INSERM, University of Nantes

5:00 pm
 

Evolution of a Stromal-Immune Axis in Cancer Immunology and immunotherapy
Shannon Turley, Department of Cancer Immunology, Genentech, South San Francisco, CA, USA
 
 5:30 pm Cocktail & Poster viewing session
 

DAY 2 - FRIDAY MAY 29th 2020

 

8:00 am

Coffee

8:30 am


Keynote speech - New immunotherapies in cancer and autoimmunity
Jeff Bluestone, UCSF and Parker Foundation, USA


 

SESSION III - BIOREAGENTS
Chairmen: Paolo Dellabona & Carole Guillonneau

9:00 am


 

IL-2-based immunotherapies for (dis)-engaging Tregs

Eliane Piaggio, Translational immunotherapy team U938, Institut Curie, Paris
 

9:30 am


 

Targeting Trained Immunity in Organ Transplantation
Jordi Ochando,
Icahn School of Medicine at Mount Sinai, New York City, USA

10:00 am

Oncolytic activity of attenuated Measles virus and the defects in the type I interferon response in cancer

Jean-François Fonteneau, CRCINA, INSERM U1232, LabEx IGO, Siric ILIAD, Nantes

10:30 am

Coffee break

11:00 am
 

Selected communications

  • Targeting DC-lectin receptors for anti-tumor immunity - Marion Drouin, CRTI, UMR 1064 INSERM, University of Nantes
  • Agonist anti-ChemR23 mAb blunts tissue neutrophil accumulation and triggers chronic colitis inflammation resolution - Charlène Trilleaud, CRTI, UMR 1064 INSERM, University of Nantes
  • Blocking PDGFRα signaling ameliorates multiple sclerosis-like neuroinflammation by inhibiting disruption of the blood brain barrier - Manuel Zeitelhofer, Karolinska Institute, MBB, Vascular Biology Unit, Stockholm, Sweden
11:30 am

Harnessing Innate Immunity in Cancer Therapy

Eric Vivier, Aix Marseille University, APHM, CNRS, INSERM, CIML / Hôpital de la Timone, Marseille-Immunopole / Innate Pharma Research Laboratories, Marseille, France

 

12:00 am

Lunch break


 


SESSION IV - NEW HORIZONS
Chairmen: Megan Sykes & Catherine Rabu
CGO  SIRIC ILIAD

1:30 pm

Targeting common epithelial malignancies withTCR engineered lymphocytes specific for 'public' neoantigens
Christopher Klebanoff, Memorial Sloan Kettering Cancer Center and the Parker Institute for Cancer Immunotherapy, New York, USA

2:00 pm

   Deep Profiling of Tissue Ecosystems by Imaging Mass Cytometry
   Nicolas Damond, Department of Quantitative Biomedicine, University of Zurich, Switzerland

2:30 pm

Selected communications
 

  • The myeloid lineage is required for the emergence of a regeneration permissive environment following Xenopus tail amputation - Jerome Jullien, Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge, Cambridge, UK
  • Impact of inflammation on the specific CD4+ T cell and antibody responses during antigen expression in the mouse liver - Anaïs Cardon, CRTI, UMR 1064 INSERM, University of Nantes
  • Characterizing the BK polyomavirus-specific B-cell repertoire in kidney transplant recipients with BK reactivation - Dorian McIlroy, CRTI, UMR 1064 INSERM, University of Nantes

3:00 pm

Coffee break

3:30 pm

Mesenchymal stromal cell heterogeneity: implication for their clinical application
Karin Tarte, Inserm U1236, University of Rennes, Rennes University Hospital, France
 

4:00 pm

Reconstructing the human immune system using single cell genomics
Muzlifah Haniffa, Wellcome, Lister Institute, Newcastle Biomedical Research Centre, Institute of Cellular Medicine, Newcastle University, UK

4:30 pm

Awarding ceremony (best oral presentation, best poster)